Recent News

• 08.07.2026 - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 08.05.2026 - Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
• 07.16.2026 - Arcutis Expands Board of Directors with Appointment of Chris Peetz
• 07.15.2026 - Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026
• 07.08.2026 - FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
• 07.02.2026 - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 06.30.2026 - Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications
• 06.29.2026 - FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
• 06.05.2026 - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 06.03.2026 - New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology

Recent Filings

• 08.07.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.05.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.05.2026 - 8-K Current report
• 08.05.2026 - EX-99.1 EX-99.1
• 08.03.2026 - 144 Report of proposed sale of securities
• 08.03.2026 - 144 Report of proposed sale of securities
• 08.03.2026 - 144 Report of proposed sale of securities